All In Biotech

Drug Trial Radar · NCT06568627

A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

A Multicenter, Prospective, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of Venous Leg Ulcers (VALUE)

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 216 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

216

Planned (sponsor's estimate)

Start

Jun 1, 2025

Primary completion

Dec 2026

Study completion Mar 2027

Sponsor

Lead sponsor
MediWound LtdIndustry
Sponsor type
Industry
First posted
Aug 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is: To assess the efficacy and safety of EscharEx (EX-03 5% formulation) compared to placebo control,in debridement and wound bed preparation of Venous Leg Ulcers (VLU).

Conditions

  • Venous Leg Ulcer (VLU)

Interventions

  • EscharEx (EX-03)Drug

    a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.

  • Placebo (Gel vehicle)Drug

    A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of complete debridement, clinically (visually) assessed after each applicationTime frame: up to 2 weeks
  2. Facilitation of wound closure, clinically assessed, as measured by time to complete wound closureTime frame: up to 12 weeks

Locations

60 sites in 9 countries. Site status is shown where the registry gives one.

  • Synergy Wound 360, PLLC

    Phoenix, Arizona · Not yet recruiting

  • Limb Preservation Platform, Inc

    Fresno, California · Recruiting

  • Angel City Research,Inc

    Los Angeles, California · Recruiting

  • North Park Podiatry

    San Diego, California · Not yet recruiting

  • Center for Clinical Research INC

    San Francisco, California · Recruiting

  • ILD Research Center

    Vista, California · Recruiting

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia · Not yet recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Withdrawn

  • Boston Medical Center

    Boston, Massachusetts · Recruiting

  • Rutgers New Jersey Medical Center

    Newark, New Jersey · Recruiting

  • Northwell Health Comprehensive Wound Healing Center

    Lake Success, New York · Recruiting

  • NYU Langone Health Long Island - Research & Academic Center

    Mineola, New York · Recruiting

  • Mount Sinai West

    New York, New York · Recruiting

  • Cutting Edge Research LLC.,

    Circleville, Ohio · Recruiting

  • Oregon Health & Science University

    Portland, Oregon · Not yet recruiting

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Not yet recruiting

  • Clinical Trial Network Houston

    Houston, Texas · Recruiting

  • Woundcentrics, LLC

    San Antonio, Texas · Withdrawn

  • Medical University of Graz

    Graz, Austria · Recruiting

  • Medical University Wien

    Vienna, Austria · Recruiting

  • Scarborough Health Network

    Thornhill, Ontario (ON), Canada · Not yet recruiting

  • Helios Klinikum Berlin-Buch

    Berlin, Germany · Not yet recruiting

  • Ruhr-University Bochum

    Bochum, Germany · Recruiting

  • Städtisches Klinikum Dresden

    Dresden, Germany · Withdrawn

  • Wundzentrum Dermatologie Erlangen

    Erlangen, Germany · Recruiting

  • DermaKiel - Allergie und Haut Centrum

    Kiel, Germany · Terminated

  • TUM Klinikum rechts der Isar

    München, Bavaria, Germany · Recruiting

  • DRK Hospital Chemnitz-Rabenstein

    Chemnitz, Saxony (Sachsen), Germany · Not yet recruiting

  • Asaf Harofeh (Shamir) Medical Center

    Be’er Ya‘aqov, Israel · Recruiting

  • Sheba Medical Center

    Ramat Gan, Israel · Recruiting

  • Kaplan Medical Center

    Rehovot, Israel · Recruiting

  • Rabin Medical Center

    Petah Tikva, Central District, Israel · Not yet recruiting

  • Galilee Medical Center

    Nahariya, Northern District, Israel · Recruiting

  • Soroka Medical Center

    Beersheba, Southern District, Israel · Not yet recruiting

  • Aurelia Hospital Roma

    Roma, Italy · Recruiting

  • Ospedale Perrino Brindisi

    Brindisi, Apulia, Italy · Recruiting

  • Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli

    Naples, Campania, Italy · Not yet recruiting

  • Ospedale Villa Scassi

    Genoa, Liguria, Italy · Not yet recruiting

  • Ospedale S. Chiara

    Pisa, Tuscany (Toscana), Italy · Not yet recruiting

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.